Abstract Number: 1432 • 2017 ACR/ARHP Annual Meeting
The Prognostic Value of IgA Subtypes of Rheumatoid Factor and Anti-Citrullinated Protein Antibodies (ACPA) for Prediction of Therapeutic Responses to TNF Inhibitory Therapy in Patients with Rheumatoid Arthritis
Background/Purpose: Rheumatoid factor (RF) and Anti-Citrullinated Protein antibodies (ACPA) are the most specific diagnostic markers of rheumatoid arthritis (RA). These antibodies are predominantly of the…Abstract Number: 1433 • 2017 ACR/ARHP Annual Meeting
Tailoring Second-Line Biologic Therapy in Rheumatoid Arthritis: New Findings on the Usefulness of Antibody Status to Optimise Drug Selection
Background/Purpose: Treatment of rheumatoid arthritis (RA) has been revolutionized by the introduction of Tumour Necrosis Factor alpha inhibitors (TNFi). However a significant proportion of patients…Abstract Number: 1434 • 2017 ACR/ARHP Annual Meeting
COX-2 Inhibitor Contributes Cell Death in Rheumatoid Arthritis Fibroblast-like Synoviocytes Via PI3K/AKT/mTOR Signaling Pathway Triggered By Autophagy
Background/Purpose: Recently, the possibilities that autophagy regulates apoptosis resistance and hyperplasia of fibroblast-like synoviocytes (FLS) were also presented. The aim of this study is to…Abstract Number: 1435 • 2017 ACR/ARHP Annual Meeting
Consistent Inhibition of Joint Destruction By Denosumab in Important Subgroups of Japanese Patients with Rheumatoid Arthritis: Pooled Analysis of Phase 2 and 3 Studies
Background/Purpose: Denosumab is a fully human monoclonal antibody (IgG2 subclass) that inhibits bone resorption by blocking RANKL. Phase 2 (DRIVE) and phase 3 (DESIRABLE) studies…Abstract Number: 1436 • 2017 ACR/ARHP Annual Meeting
Therapeutic Drug Monitoring on Rheumatoid Arthritis Patients with Reduced Doses of Intravenous Tocilizumab
Background/Purpose: Tocilizumab (TCZ) is an effective treatment for rheumatoid arthritis (RA). There is great variability in intravenous (iv) TCZ serum concentrations among individuals. Moreover, initial…Abstract Number: 1437 • 2017 ACR/ARHP Annual Meeting
C-Reactive Protein Levels in Patients with or without Structural Progression: A Post-Hoc Analysis from a Phase 3 Tofacitinib Trial
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). We examined high sensitivity C-reactive protein (hsCRP) levels in relation…Abstract Number: 1438 • 2017 ACR/ARHP Annual Meeting
Is It Necessary to Weight By Weight the Dosage of MTX in RA Patients? Results from Obsevational Analysis of Baseline Data of a Phase III Trial
Background/Purpose: In inflammatory rheumatic diseases, pharmacokinetics of MTX may be modified by patients’ weight [1]. The rheumatologists are though reluctant to prescribe a high dosage…Abstract Number: 1439 • 2017 ACR/ARHP Annual Meeting
Factors Influencing the Prescription of Tocilizumab Alone or in Combination with Dmards in Rheumatoid Arthritis Patients in a Real Life Setting. Pooled Analysis of 2 Observational Studies
Background/Purpose: Tocilizumab (TCZ) as monotherapy (Mono) is nowadays a standard treatment in rheumatoid arthritis (RA) for patients in whom methotrexate (MTX) gives an inadequate response1.…Abstract Number: 1440 • 2017 ACR/ARHP Annual Meeting
The Effectiveness of Zoster Vaccine in RA Patients Subsequently Treated with Tofacitinib
Background/Purpose: RA patients (pts) are at increased risk of herpes zoster (HZ), and ACR guidelines recommend vaccination in pts aged ≥50 years prior to starting…Abstract Number: 1441 • 2017 ACR/ARHP Annual Meeting
Evaluation of Ultrasound-Detecting Efficacy of Abatacept By Profiling Multiple Serum Cytokines, Chemokines and Bone-Related Biomarkers in Rheumatoid Arthritis Patients: Kyushu Multicenter Rheumatoid Arthritis Ultrasound Prospective Observational Cohort Study
Background/Purpose: We have been prospectively investigating therapeutic efficacy of biologic or targeted synthetic DMARDs in patients with rheumatoid arthritis (RA) by ultrasound (US) in Kyushu…Abstract Number: 1442 • 2017 ACR/ARHP Annual Meeting
Corticosteroid Sparing Effect of Non-TNF Targeted Biologics, Rituximab, Abatacept and Tocilizumab in Common Practice: Data from 3183 Patients Enrolled in the French Society of Rheumatology Registries
Background/Purpose: Little is known regarding the corticosteroid sparing effect of non-TNF biologics in rheumatoid arthritis (RA). Objectives : To compare the corticosteroid sparing effect of…Abstract Number: 1443 • 2017 ACR/ARHP Annual Meeting
Adverse Drug Reactions Due to Disease Modifying Drugs in a Cohort of Patients with Incident Rheumatoid Arthritis
Background/Purpose: There is a well-known risk of developing adverse drug reactions (ADR) in rheumatology due, mainly, to the Disease Modifying Drugs (DMARD) used. After more…Abstract Number: 1444 • 2017 ACR/ARHP Annual Meeting
Targeted Therapeutic Delivery to Cartilage with Knottin Proteins
Background/Purpose: Arthritic diseases affect more than 50 million Americans and, although there are many etiologies, the common manifestation of the disease is pain and limited…Abstract Number: 1445 • 2017 ACR/ARHP Annual Meeting
Effect of Methotrexate (MTX), and MTX Plus Colchicine (CCH) on the Expression and Activity of NLRP3 Inflammasome in Patients with Early Rheumatoid Arthritis (RA)
Background/Purpose: NLRP3 inflammasome is an intracellular protein complex involved in the production of pro-inflammatory cytokines as IL-1β and IL-18, which has been reported to have…Abstract Number: 1446 • 2017 ACR/ARHP Annual Meeting
Clinical Significance of Serum Levels of ROM (reactive oxygen metabolities) at 12 Weeks during Treatment with Biologic Agents As a Predictor for the 52-Week Remission
Background/Purpose: Oxidative stress induced by reactive oxygen species is thought to be an important mechanism that underlies joint destruction and synovial proliferation. We have shown…
ACR Meeting Abstracts